SCHEMBL3116997

SCHEMBL3116997

Cn1c(Nc2ccccc2)nccc1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 2/20 0.50
CCND1 P24385 2/20 0.50
CCND2 P30279 2/20 0.50
CCND3 P30281 2/20 0.50
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
CYP1A2 P05177 3/20 0.47
USP2 O75604 3/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
MAPK1 P28482 2/20 0.47
TSHR P16473 1/20 0.47
POLB P06746 2/20 0.45
ALDH1A1 P00352 1/20 0.44
CYP2D6 P10635 1/20 0.41
KDR P35968 1/20 0.40
PLK1 P53350 1/20 0.40
PTK2 Q05397 1/20 0.40
DHODH Q02127 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9378857 0.80 CDK4 (0.52) CDK4CCND1CCND2CCND3POLB
SCHEMBL12561198 0.75 CYP1A2 (0.48) CDK4CCND1CCND2CCND3MEN1
SCHEMBL17951560 0.74 KMT2A (0.42) MEN1KMT2AMAPK1TSHRPOLB
SCHEMBL2278282 0.73 WEE1 (0.45) CDK4CCND1CCND2CCND3MEN1
SCHEMBL11481093 0.73 ALDH1A1 (0.47) CDK4CCND1CCND2CCND3MEN1
SCHEMBL11830686 0.73 FDPS (0.54) CYP1A2CYP3A4CYP2C9CYP2C19MAPK1
SCHEMBL12411881 0.72 BRD4 (0.44) CDK4CCND1CCND2CCND3MEN1
SCHEMBL12376777 0.72 CYP1A2 (0.43) CDK4CCND1CCND2CCND3MEN1
SCHEMBL12848057 0.72 CDK4 (0.45) CDK4CCND1CCND2CCND3MEN1
SCHEMBL13726378 0.70 HPGDS (0.45) CYP1A2ALDH1A1KDRNR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE GAUDINO JOHN 2011-03-03 US disclosed
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2010-10-07 US disclosed
US-7723330-B2 Heterobicyclic pyrazole compounds and methods of use ARRAY BIOPHARMA INC. (US) 2010-05-25 US disclosed
EP-2032538-A2 QUINOLINE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2009-03-11 EP disclosed
EP-2001880-A2 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2008-12-17 EP disclosed
WO-2007146824-A2 QUINOLINE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-12-21 WO disclosed
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use GENENTECH, INC. 2007-10-11 US disclosed
WO-2007103308-A2 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ROR1, CYP11B1, CYP11B2 CDK4 194/4885CCND1 1823/4885CCND2 1781/4885
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use ROR1, CYP11B1, CYP11B2 CDK4 194/4885CCND1 1823/4885CCND2 1781/4885
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE TK1, ABL1, ROR1 CDK4 59/4885CCND1 260/4885CCND2 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.